Vulvar premalignant lesions and cancer: what's new in diagnosis, treatment, and rehabilitation?
A. G. Solopova,
V. O. Bitsadze,
A. V. Lazarchuk,
N. A. Makatsariya,
M. A. Tishchenko,
D. O. Utkin,
D. V. Blinov https://doi.org/10.17749/2313-7347/ob.gyn.rep.2026.776
Abstract
Vulvar premalignant lesions and vulvar cancer represent a significant issue in modern gynecologic oncology. The importance of this problem is driven by the increasing incidence, the impact on patients’ quality of life, and the difficulty of early-stage diagnosis. In recent decades, understanding of the pathogenesis, classification, and treatment approaches for such pathologies has been dramatically changed. This review presents current data on the epidemiology, classification, molecular mechanisms of development, diagnostic methods as well as treatment of vulvar premalignant lesions and vulvar cancer. Special attention is paid to the role played by immunohistochemical markers, novel non-invasive diagnostic methods, and organ-preserving therapeutic approaches. Issues of secondary prevention, including HPV vaccination, as well as modern rehabilitation strategies aimed to improve patients’ quality of life are also outlined.
About the Authors
A. G. Solopova
Sechenov University
Russian Federation
Russian Federation
Antonina G. Solopova, MD, Dr Sci Med, Prof.
Scopus Author ID: 6505479504. WoS ResearcherID: Q-1385-2015
8 bldg. 2, Trubetskaya Str., Moscow 119048
V. O. Bitsadze
Sechenov University
Russian Federation
Russian Federation
Victoria O. Bitsadze, MD, Dr Sci Med, Prof., Professor of RAS
Scopus Author ID: 6506003478. WoS ResearcherID: F-8409-2017
8 bldg. 2, Trubetskaya Str., Moscow 119048
A. V. Lazarchuk
Sechenov University
Russian Federation
Russian Federation
Arina V. Lazarchuk, MD.
8 bldg. 2, Trubetskaya Str., Moscow 119048
N. A. Makatsariya
Sechenov University
Russian Federation
Russian Federation
Nataliya A. Makatsariya, MD, PhD.
WoS ResearcherID: F-8406-2017
8 bldg. 2, Trubetskaya Str., Moscow 119048
M. A. Tishchenko
Moscow City Oncology Hospital No. 62
Russian Federation
Russian Federation
Marina A. Tishchenko, MD.
27 bldg 1–30, Istra Village, Moscow Region 143515
D. O. Utkin
Yudin City Clinical Hospital, Moscow Health Department
Russian Federation
Russian Federation
Dmitry O. Utkin, MD, PhD.
4 Kolomensky Proezd, Moscow 115446
D. V. Blinov
Institute for Preventive and Social Medicine; Moscow Haass Medical – Social Institute; Scientific and Clinical Center for Medical Rehabilitation and Balneology, Federal Medical-Biological Agency
Russian Federation
Russian Federation
Dmitry V. Blinov, MD, Dr Sci Med.
Scopus Author ID: 6701744871.
WoS ResearcherID: E-8906-2017
11–13/1 Lyalin Pereulok, Moscow 101000
5 bldg. 1–1a, 2-ya Brestskaya Str., Moscow 123056
6 bldg. 1, Rodnikovaya Str., Village Goluboe, Moscow region 141551
References
1. Dockery L.E., Soper J.T. Vulvar intraepithelial neoplasia: a review of the disease and current managemen. Obstet Gynecol Surv. 2021;76(1):55–62. https://doi.org/10.1097/OGX.0000000000000857.
2. Bodelon C., Madeleine M.M., Voigt L.F., Weiss N.S. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control. 2009;20(9):1779–82. https://doi.org/10.1007/s10552-009-9418-8.
3. Capria A., Tahir N., Fatehi M. Vulvar cancer. Treasure Island (FL): StatPearls Publishing, 2026.
4. Judson P.L., Habermann E.B., Baxter N.N. et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107(5):1018– 22. https://doi.org/10.1097/01.AOG.0000210268.57527.a1.
5. Baandrup L., Varbo A., Munk C. et al. In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978-2007 – a nationwide populationbased study. Gynecol Oncol. 2011;122(1):45–9. https://doi.org/10.1016/j.ygyno.2011.03.016.
6. Brinton L.A., Thistle J.E., Liao L.M., Trabert B. Epidemiology of vulvar neoplasia in the NIH-AARP Study. Gynecol Oncol. 2017;145(2):298–304. https://doi.org/10.1016/j.ygyno.2017.02.030.
7. Ahr A., Rody A., Kissler S. et al. Risikofaktoren der Rezidivhäufigkeit von vulvären intraepithelialen Neoplasien Grad III (VIN III). [Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III)]. Zentralbl Gynakol. 2006;128(6):347–51. (In German). https://doi.org/10.1055/s-2006-942280.
8. Wilkinson E.J., Cox J.T., Selim M.A., O'Connor D.M. Evolution of terminology for human-papillomavirus-infection-related vulvar squamous intraepithelial lesions. J Low Genit Tract Dis. 2015;19(1):81–7. https://doi.org/10.1097/LGT.0000000000000049.
9. Höhn A.K., Brambs C.E., Hiller G.G.R. et al. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe und Frauenheilkunde. 2021;81(10):1145–53. https://doi.org/10.1055/a-1545-4279.
10. Garland S.M., Insinga R.P., Sings H.L. et al. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1777–84. https://doi.org/10.1158/1055-9965.EPI-09-0067.
11. Schiffman M., Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(4):553–60. https://doi.org/10.1158/1055-9965.EPI-121406.
12. McLaughlin-Drubin M.E., Münger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009;143(2):195–208. https://doi.org/10.1016/j.virusres.2009.06.008.
13. Harden M.E., Munger K. Human papillomavirus molecular biology. Mutat Res Rev. 2017;772:3–12. https://doi.org/10.1016/j.mrrev.2016.07.002.
14. Klaes R., Friedrich T., Spitkovsky D. et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92(2):276–84. https://doi.org/10.1002/ijc.1174.
15. Giunco S., Del Mistro A., Morello M. et al. From infection to immortality: the role of HPV and telomerase in head and neck cancer. Oral Oncol. 2025;161:107169. https://doi.org/10.1016/j.oraloncology.2024.107169.
16. Jung H.M., Phillips B.L., Chan E.K. miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ. Mol Cancer. 2014;13:80. https://doi.org/10.1186/1476-4598-13-80.
17. He H., Liu X., Liu Y. et al. Human papillomavirus E6/E7 and long noncoding RNA TMPOP2 mutually upregulated gene expression in cervical cancer cells. J Virol. 2019;93(8):e01808-18. https://doi.org/10.1128/JVI.01808-18.
18. Kiamba E.W., Goodier M.R., Clarke E. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297. https://doi.org/10.3389/fimmu.2025.1591297.
19. Mota F., Rayment N., Chong S. et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol. 1999;116(1):33–40. https://doi.org/10.1046/j.1365-2249.1999.00826.x.
20. Østergård S., Vorbeck C.S., Meinert M. Vulvar intraepithelial neoplasia. Ugeskr Laeger. 2018;180(20):V12170931.
21. ACOG Committee Opinion No. 509: Management of vulvar intraepithelial neoplasia. Obstet Gynecol. 2011;118(5):1192–4. https://doi.org/10.1097/AOG.0000000000001839.
22. Day T., Marzol A., Pagano R. et al. Clinicopathologic diagnosis of differentiated vulvar intraepithelial neoplasia and vulvar aberrant maturation. J Low Genit Tract Dis. 2020;24(4):392–98. https://doi.org/10.1097/LGT.0000000000000569.
23. Singh N., Leen S.L., Han G. et al. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol. 2015;39(1):52–60. https://doi.org/10.1097/PAS.0000000000000291.
24. Tessier-Cloutier B., Kortekaas K.E., Thompson E. et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. 2020;33(8):1595–605. https://doi.org/10.1038/s41379-020-0524-1.
25. Yang B., Hart W.R. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am J Surg Pathol. 2000;24(3):429–41. https://doi.org/10.1097/00000478-200003000-00013.
26. Al-Bannai R., Miller D., Sadownik L. et al. Vulvar acanthosis with altered differentiation (VAAD): report of a case with progression to poorly differentiated carcinoma over a 5-year period. Int J Gynecol Pathol. 2015;34(4):385–9. https://doi.org/10.1097/PGP.0000000000000182.
27. Jenkins T.M., Mills A.M. Putative precancerous lesions of vulvar squamous cell carcinoma. Semin Diagn Pathol. 2021;38(1):27–36. https://doi.org/10.1053/j.semdp.2020.09.006.
28. Sandhu R., Min Z., Bhanot N. A gigantic anogenital lesion: BuschkeLowenstein tumor. Case Rep Dermatol Med. 2014;2014:650714. https://doi.org/10.1155/2014/650714.
29. Sato H., Murakami K., Otani T. et al. Tubulovillous adenoma with highgrade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report. Diagn Pathol. 2022;17(1):85. https://doi.org/10.1186/s13000-022-01268-7.
30. Preti M., Scurry J., Marchitelli C.E., Micheletti L. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1051–62. https://doi.org/10.1016/j.bpobgyn.2014.07.010.
31. Kesić V., Vieira-Baptista P., Stockdale C.K. Early diagnostics of vulvar intraepithelial neoplasia. Cancers (Basel). 2022;14(7):1822. https://doi.org/10.3390/cancers14071822.
32. Gupta S., Ahuja S., Kalwaniya D.S. et al. Vulval premalignant lesions: a review article. Obstet Gynecol Sci. 2024;67(2):169–85. https://doi.org/10.5468/ogs.23274.
33. Micheletti L., Bogliatto F., Lynch P.J. Vulvoscopy: review of a diagnostic approach requiring clarification. J Reprod Med. 2008;53(3):179–82.
34. Heller D.S., Day T., Allbritton J. et al. Diagnostic criteria for differentiated vulvar intraepithelial neoplasia and vulvar aberrant maturation. J Low Genit Tract Dis. 2021;25(1):57–70. https://doi.org/10.1097/LGT.0000000000000572.
35. Dasgupta S., de Jonge E., Van Bockstal M.R. et al. Histological interpretation of differentiated vulvar intraepithelial neoplasia (dVIN) remains challenging-observations from a bi-national ring-study. Virchows Arch. 2021;479(2):305–15. https://doi.org/10.1007/s00428021-03070-0.
36. Schechter S.A., Chan M.P., Muthusamy S. et al. Interobserver agreement across subspecialties for diagnosis of differentiated vulvar intraepithelial neoplasia and predictive values of 20 histologic features. Arch Pathol Lab Med. 2023;147(12):1431–7. https://doi.org/10.5858/arpa.2022-0088-OA.
37. van den Einden L.C.G., de Hullu J.A., Massuger L.F. et al. Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia. Mod Pathol. 2013;26(6):874–80. https://doi.org/10.1038/modpathol.2012.235.
38. Bigby S.M., Eva L.J., Fong K.L., Jones R.W. The natural history of vulvar intraepithelial neoplasia, differentiated type: evidence for progression and diagnostic challenges. Int J Gynecol Pathol. 2016;35(6):574–84. https://doi.org/10.1097/PGP.0000000000000280.
39. Peng J., Li Y., Sun X. et al. Case report: diagnostic challenges in differentiated-type vulvar intraepithelial neoplasia. Front Oncol. 2025;15:1662088. https://doi.org/10.3389/fonc.2025.1662088.
40. Jin C., Liang S. Differentiated vulvar intraepithelial neoplasia: a brief review of clinicopathologic features. Arch Pathol Lab Med. 2019;143(6):768–71. https://doi.org/10.5858/arpa.2018-0019-RS.
41. Li Z., Liu P., Wang Z. et al. Prevalence of human papillomavirus DNA and p16INK4a positivity in vulvar cancer and vulvar intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2023;24(4):403–14. https://doi.org/10.1016/S1470-2045(23)00066-9.
42. Thuijs N.B., van Beurden M., Duin S. et al. High-grade vulvar intraepithelial neoplasia: comprehensive characterization and long-term vulvar carcinoma risk. Histopathology. 2024;84(2):301–14. https://doi.org/10.1111/his.15050.
43. Zare S.Y., Fard E.V., Fadare O. GATA3 immunohistochemistry as a diagnostic adjunct for differentiated vulvar intraepithelial neoplasia: utility and limitations. Hum Pathol. 2023;139:55–64. https://doi.org/10.1016/j.humpath.2023.07.005.
44. Abu-Rustum N.R., Yashar C.M., Arend R. et al. Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(2):117–35. https://doi.org/10.6004/jnccn.2024.0013.
45. Voss F.O., Thuijs N.B., Duin S. et al. Clinical validation of methylation biomarkers for optimal detection of high-grade vulvar intraepithelial neoplasia. Int J Cancer. 2023;153(4):783–91. https://doi.org/10.1002/ijc.34537.
46. Huisman B.W., Pagan L., Ulrich M. et al. Reflectance confocal microscopy as a non-invasive imaging tool in vulvar high-grade squamous intraepithelial lesions and lichen sclerosus: a descriptive morphological study in patients and healthy volunteers. Exp Dermatol. 2023:32(10):1734–43. https://doi.org/10.1111/exd.14888.
47. Weber A., Zimmermann C., Mausberg A.K. et al. Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and GardiquimodTM. Int Immunopharmacol. 2013;17(2):427–31. https://doi.org/10.1016/j.intimp.2013.06.023.
48. Tristram A., Hurt C.N., Madden T. et al. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15(12):1361–8. https://doi.org/10.1016/S14702045(14)70456-5.
49. Pepas L., Kaushik S., Nordin A. et al. Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev. 2011;(4):CD007924. https://doi.org/10.1002/14651858.CD007924.pub3.
50. Lawrie T.A., Nordin A., Chakrabarti M. et al. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database Syst Rev. 2016;(1):CD011837. https://doi.org/10.1002/14651858.CD011837.pub2.
51. Simões A.C., Sarmento A.C., Aquino A.C. et al. Treatment interventions for usual-type vulvar intraepithelial neoplasia: a systematic review and metaanalysis. J Low Genit Tract Dis. 2025;29(4):365–72. https://doi.org/10.1097/LGT.0000000000000901.
52. Michener C.M., Ricci S., AlHilli M. et al. Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3. Gynecol Oncol. 2023;178:102–9. https://doi.org/10.1016/j.ygyno.2023.10.003.
53. Daayana S., Winters U., Stern P.L., Kitchener H.C. Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia. Photochem Photobiol Sci. 2011;10(5):802–9. https://doi.org/10.1039/c0pp00344a.
54. Zarochentseva N.V., Dzhidzhikhiia L.K. Vulvar intraepithelial neoplasia: current approach to the problem. [Intraepitelial'naya neoplaziya vul'vy: sovremennyj vzglyad na problemu]. Rossijskij vestnik akusheraginekologa. 2020;20(1):44–53. (In Russ.). https://doi.org/10.17116/rosakush20202001144.
55. He M.Y., Yu E.L., Hui S.K., Kung Y.L.F. Clinical outcomes of laser vaporization for vaginal intraepithelial neoplasia – a 20-year retrospective review. Eur J Obstet Gynecol Reprod Biol. 2022;277:101–9. https://doi.org/10.1016/j.ejogrb.2022.08.017.
56. Leufflen L., Baermann P., Rauch P. et al. Treatment of vulvar intraepithelial neoplasia with CO(2) laser vaporization and excision surgery. J Low Genit Tract Dis. 2013;17(4):446–51. https://doi.org/10.1097/LGT.0b013e318284c1ed.
57. Lebreton M., Carton I., Brousse S. et al. Vulvar intraepithelial neoplasia: classification, epidemiology, diagnosis, and management. J Gynecol Obstet Hum Reprod. 2020;49(9):101801. https://doi.org/10.1016/j.jogoh.2020.101801.
58. Di Donato V., Caruso G., Bogani G. et al. HPV vaccination after primary treatment of HPV-related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis. Vaccines (Basel). 2022;10(2):239. https://doi.org/10.3390/vaccines10020239.
59. Sayer-Jones K., Sherman K.A. Body image concerns in individuals diagnosed with benign gynaecological conditions: scoping review and meta-synthesis. Health Psychol Behav Med. 2021;9(1):456–79. https://doi.org/10.1080/21642850.2021.1920949.
60. Charatsi D., Vanakara P., Evaggelopoulou E. et al. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors. Medicine (Baltimore). 2022;101(4):e28705. https://doi.org/10.1097/MD.0000000000028705.
61. Buzzaccarini G., Marin L., Noventa M. et al. Hyaluronic acid in vulvar and vaginal administration: evidence from a literature systematic review. Climacteric. 2021;24(6):560–71. https://doi.org/10.1080/13697137.2021.1898580.
62. Wu X., Zheng X., Yi X. et al. Electromyographic biofeedback for stress urinary incontinence or pelvic floor dysfunction in women: a systematic review and meta-analysis. Adv Ther. 2021;38(8):4163–77. https://doi.org/10.1007/s12325-021-01831-6.
63. Female sexual dysfunction: ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician–Gynecologists, Number 213. Obstet Gynecol. 2019;134(1):e1–е18. https://doi.org/10.1097/AOG.0000000000003324.
64. Pagan L., Huisman B.W., van der Wurff M. et al. The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions. Front Microbiol. 2023;14:1264768. https://doi.org/10.3389/fmicb.2023.1264768.
65. Oonk M.H.M., Planchamp F., Baldwin P. et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer – Update 2023. Int J Gynecol Cancer. 2023;33(7):1023–43. https://doi.org/10.1136/ijgc-2023-004486.
66. Weinberg D., Gomez-Martinez R.A. Vulvar cancer. Obstet Gynecol Clin North Am. 2019;46(1):125–35. https://doi.org/10.1016/j.ogc.2018.09.008.
67. Huang J., Chan S.C., Fung Y.C. et al. Global incidence, risk factors and trends of vulvar cancer: a country-based analysis of cancer registries. Int J Cancer. 2023;153(10):1734–45. https://doi.org/10.1002/ijc.34655.
68. Alkatout I., Schubert M., Garbrecht N. et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305–13. https://doi.org/10.2147/IJWH.S68979.
69. Tan A., Bieber A.K., Stein J.A., Pomeranz M.K. Diagnosis and management of vulvar cancer: a review. J Am Acad Dermatol. 2019;81(6):1387–96. https://doi.org/10.1016/j.jaad.2019.07.055.
70. King A., Harris W., Campbell Z. et al. Efficacy of ultrasound in the evaluation of inguinal lymph nodes in patients with vulvar cancer: an updated systematic review and meta-analysis. Int J Gynecol Cancer. 2026;36(2):102865. https://doi.org/10.1016/j.ijgc.2025.102865.
71. Miccò M., Russo L., Persiani S. et al. MRI in the evaluation of locally advanced vulvar cancer treated with chemoradiotherapy and vulvar cancer recurrence: the 2021 revision of FIGO classification and the need for multidisciplinary management. Cancers (Basel). 2022;14(16):3852. https://doi.org/10.3390/cancers14163852.
72. Gui B., Persiani S., Miccò M. et al. MRI staging in locally advanced vulvar cancer: from anatomy to clinico-radiological findings. A multidisciplinary VulCan team point of view. J Pers Med. 2021;11(11):1219. https://doi.org/10.3390/jpm11111219.
73. Heaps J.M., Fu Y.S., Montz F.J. et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990;38(3):309–14. https://doi.org/10.1016/00908258(90)90064-r.
74. Nooij L.S., van der Slot M.A., Dekkers O.M. et al. Tumour-free margins in vulvar squamous cell carcinoma: does distance really matter? Eur J Cancer. 2016;65:139–49. https://doi.org/10.1016/j.ejca.2016.07.006.
75. Woelber L., Griebel L.F., Eulenburg C. et al. Role of tumour-free margin distance for loco-regional control in vulvar cancer – a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. Eur J Cancer. 2016;69:180–8. https://doi.org/10.1016/j.ejca.2016.09.038.
76. Raimond E., Delorme C., Ouldamer L. et al. Surgical treatment of vulvar cancer: Impact of tumor-free margin distance on recurrence and survival. A multicentre cohort analysis from the Francogyn study group. Eur J Surg Oncol. 2019;45(11):2109–14. https://doi.org/10.1016/j.ejso.2019.07.005.
77. Höckel M., Trott S., Dornhöfer N. et al. Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial. Lancet Oncol. 2018;19(4):537–48. https://doi.org/10.1016/S1470-2045(18)30109-8.
78. Rychlik A., Bidzinski M., Rzepka J., Piatek S. Sentinel lymph node in vulvar cancer. Chin Clin Oncol. 2021;10(2):19. https://doi.org/10.21037/cco-20-202.
79. Natesan D., Susko M., Havrilesky L., Chino J. Definitive chemoradiotherapy for vulvar cancer. Int J Gynecol Cancer. 2016;26(9):1699–705. https://doi.org/10.1097/IGC.0000000000000811.
80. Dhanis J., Strijker D., Drager L. et al. Feasibility of Introducing a prehabilitation program into the care of gynecological oncology patients – a single institution experience. Cancers (Basel). 2024;16(5):1013. https://doi.org/10.3390/cancers16051013.
81. Akavova S.A. Necessity and advisability of pre-rehabilitation in cancer patients before planned surgery: a rationale for the approach. [Neobkhodimost' i tselesoobraznost' prereabilitatsii u onkologicheskikh patsientov pered planovym khirurgicheskim vmeshatel'stvom: obosnovanie podkhoda]. Journal of Medical Rehabilitation. 2025;3(4):231–41. (In Russ.). https://doi.org/10.17749/2949-5873/rehabil.2025.73.
82. Minnella E.M., Bousquet-Dion G., Awasthi R. et al. Multimodal prehabilitation improves functional capacity before and after colorectal surgery for cancer: a five-year research experience. Acta Oncol. 2017;56(2):295–300. https://doi.org/10.1080/0284186X.2016.1268268.
83. Valkenet K., van de Port I.G., Dronkers J.J. et al. The effects of preoperative exercise therapy on postoperative outcome: a systematic review. Clin Rehabil. 2011;25(2):99–111. https://doi.org/10.1177/0269215510380830.
84. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol. 2015;22(13):4117–23. https://doi.org/10.1245/s10434-015-4550-z.
85. ACOG Committee Opinion No. 750: Perioperative Pathways: Enhanced Recovery After Surgery. Obstet Gynecol 2018;132(3):e120–e130. https://doi.org/10.1097/AOG.0000000000002818.
86. Sánchez-Iglesias J.L., Carbonell-Socias M., Pérez-Benavente M.A. et al. PROFAST: a randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery. Eur J Cancer. 2020;136:149–58. https://doi.org/10.1016/j.ejca.2020.06.011.
87. Chau J.P.C., Liu X., Lo S.H.S. et al. Perioperative enhanced recovery programmes for women with gynaecological cancers. Cochrane Database Syst Rev. 2022;3(3):CD008239. https://doi.org/10.1002/14651858.CD008239.pub5.
88. Kakkos S.K., Caprini J.A., Geroulakos G. et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2016;9(9):CD005258. https://doi.org/10.1002/14651858.CD005258.pub3.
89. Ben-Arye E., Segev Y., Galil G. et al. Acupuncture during gynecological oncology surgery: a randomized controlled trial assessing the impact of integrative therapies on perioperative pain and anxiety. Cancer. 2023;129(6):908–19. https://doi.org/10.1002/cncr.34542.
90. Xue L., Yan Y., Chen Z., Hong Y. Acupuncture and massage therapy enhance postoperative recovery and quality of life in orthopedic patients. Medicine (Baltimore). 2025;104(37):e44314. https://doi.org/10.1097/MD.0000000000044314.
91. de Bem Fretta T., Bø K., Mendes P.C.S. et al. Telerehabilitation reduced urinary incontinence, pelvic pain and dyspareunia in women after treatment for gynaecological cancer: a randomised trial. J Physiother. 2026;72(1):53–60. https://doi.org/10.1016/j.jphys.2025.12.007.
92. Kruglova L.S., Shatokhina E.A., Kotenko K.V., Korchazhkina I.B. The use of the physical therapy methods for the rehabilitation of the patients presenting with cancer pathology. [Ispol'zovanie fizioterapevticheskikh metodov v reabilitatsii bol'nykh s onkologicheskoy patologiey]. Fizioterapiya, bal'neologiya i reabilitaciya. 2016;15(2):97–101. (In Russ.) https://doi.org/10.18821/1681-3456-2016-15-2-97-101.
93. Lasinski B.B., McKillip Thrift K., Squire D. et al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R. 2012;4(8):580–601. https://doi.org/10.1016/j.pmrj.2012.05.003.
94. Barlow E.L., Hacker N.F., Hussain R., Parmenter G. Sexuality and body image following treatment for early-stage vulvar cancer: a qualitative study. J Adv Nurs. 2014;70(8):1856–66. https://doi.org/10.1111/jan.12346.
95. Janda M., Obermair A., Cella D. et al. Vulvar cancer patients’ quality of life: a qualitative assessment. Int J Gynecol Cancer. 2004;14(5):875–81. https://doi.org/10.1111/j.1048-891X.2004.14524.x.
96. Philp S., Mellon A., Barnett C. et al. The road less travelled: Australian women's experiences with vulval cancer. Eur J Cancer Care. 2017;26(1):12465. https://doi.org/10.1111/ecc.12465.
97. Aerts L., Enzlin P., Vergote I. et al. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. Eur J Gynaecol Oncol. 2012;9(2):361–71. https://doi.org/10.1111/j.1743-6109.2011.02520.x.
98. Jefferies H., Clifford C. Aloneness: the lived experience of women with cancer of the vulva. Eur J Cancer Care. 2011;20(6):738–46. https://doi.org/10.1111/j.1365-2354.2011.01246.x.
99. Senn B., Gafner D., Happ M.B. et al. The unspoken disease: symptom experience in women with vulval neoplasia and surgical treatment: a qualitative study. Eur J Cancer Care. 2011;20(6):747–58. https://doi.org/10.1111/j.1365-2354.2011.01267.x.
Review
For citations:
Solopova A.G., Bitsadze V.O., Lazarchuk A.V., Makatsariya N.A., Tishchenko M.A., Utkin D.O., Blinov D.V. Vulvar premalignant lesions and cancer: what's new in diagnosis, treatment, and rehabilitation? Obstetrics, Gynecology and Reproduction. 2026;20(3):575–590. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2026.776
Views:
38
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 